<DOC>
	<DOCNO>NCT02849457</DOCNO>
	<brief_summary>Study design Phase IIb prospective multi-center , randomize , placebo-controlled , double-blind clinical trial . The goal enroll 80 infant Tuberous Sclerosis Complex le 6 month age prior onset first seizure</brief_summary>
	<brief_title>Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex</brief_title>
	<detailed_description>The central hypothesis Phase IIb trial early identification electroencephalography ( EEG ) biomarkers early treatment versus delayed treatment vigabatrin infant tuberous sclerosis complex ( TSC ) positive impact developmental outcomes 24 month age . It would also prevent low risk develop infantile spasm refractory seizure . This preventative approach would expect result favorable long-term cognitive , behavioral , developmental psychiatric outcome significantly improve overall quality life . It randomize , double-blind , placebo-controlled clinical trial design . Successful completion trial also advance field demonstrate value systematic surveillance EEG asymptomatic infant TSC .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>1 . &lt; 6months age 2 . No history seizures infantile spasm , evidence subclinical electrographic seizure previous video EEG 3 . Meet genetic clinical diagnostic criterion TSC , latter base current recommendation diagnostic evaluation , physical exam , neuroimaging , echocardiogram 1 . Has receive mammalian target rapamycin ( mTOR ) inhibitor 2 . Has receive anticonvulsant medication include vigabatrin ketogenic diet , antiseizure therapeutic agent , device , procedure . 3 . Subjects history prematurity define gestational age &lt; 30 week time delivery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>